US approves GHB-based medication for sleep disorder

The US Food and Drug Administration (FDA) has approved medication based on gamma-hydroxybutyrate (GHB) for treating idiopathic hypersomnia. The medication, Xywav, is made by Jazz Pharmaceuticals plc and is already approved for use in other sleep disorders such as narcolepsy and cataplexy. The medication has been placed under a strict prescribing control programme called Risk Evaluation and Mitigation Strategy to reduce the potential risks from taking the drug.